Update on the role of nonsteroidal anti-inflammatory drugs and coxibs in the management of acute pain

Current Opinion in Anaesthesiology

Volumn 20, Issue 5, 2007, Pages 440-450

  Reuben, Scott S ^a,b  

^a BAYSTATE MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cyclooxygenase 2; Cyclooxygenase 2 specific inhibitor; Multimodal analgesia; Nonsteroidal anti inflammatory drugs; Preemptive analgesia; Prostaglandin

Indexed keywords

ACETYLSALICYLIC ACID; BUPIVACAINE; CELECOXIB; CLONIDINE; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; KETAMINE; KETOROLAC; MORPHINE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; PARACETAMOL; PARECOXIB; PETHIDINE; PIROXICAM; ROFECOXIB; VALDECOXIB;

CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; DISEASE CONTROL; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FRACTURE HEALING; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HEALING IMPAIRMENT; HEMATOMA; HUMAN; HYPOTENSION; LOADING DRUG DOSE; LOW DRUG DOSE; META ANALYSIS; MONOTHERAPY; NAUSEA AND VOMITING; NEPHROTOXICITY; OSTEOARTHRITIS; PAIN; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PSEUDARTHROSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THROMBOCYTE DYSFUNCTION; THROMBOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ACUTE DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; HUMANS; PAIN, POSTOPERATIVE; PERIOPERATIVE CARE; TREATMENT OUTCOME;

EID: 34548686806     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/ACO.0b013e3282effb1d     Document Type: Review

References (112)

1. Apfelbaum JL, Chen C, Mehta SS, Gan TJ. Postoperative pain experience: results from a national survey suggest postoperative pain continues to be undermanaged. Anesth Analg 2003; 97:534-540.
2. Warfield CA, Kahn CH. Acute pain management. Programs in U. S. hospitals and experiences and attitudes among U. S. adults. Anesthesiology 1995; 83:1090-1094.
3. Phillips DM. JCAHO pain management standards are unveiled. JAMA 2000; 284:4-5.
4. Kehlet H. Postoperative opioid sparing to hasten recovery. What are the issues? Anesthesiology 2005; 102:1083-1085.
5. Taylor S, Voytovich AE, Kozol RA. Has the pendulum swung too far in postoperative pain control? Am J Surg 2003; 186:472-475.
6. Vila H, Smith RA, Augustyniak MJ, et al. The efficacy and safety of pain management before and after implementation of hospital-wide pain management standards: Is patient safety compromised by treatment based solely on numerical pain ratings? Anesth Analg 2005; 101:474-480.
7. Kehlet H, Dahl JB. The value of 'multimodal' or 'balanced analgesia' in postoperative pain treatment. Anesth Analg 1993; 77:1048-1056.
8. Ashburn MA, Caplan RA, Carr DB, et al. Practice guidelines for acute pain management in the perioperative setting. An updated report by the American Society of Anesthesiologists task force on acute pain management. Anesthesiology 2004; 100:1573-1581.
9. United States Acute Pain Management Guideline Panel. Acute Pain Management: Operative or Medical Procedures and Trauma. Pub. no. 92-0032. Rockville, Maryland: United States Department of Health and Human Services, Public Health Service Agency for Healthcare Policy and Research; 1992.
10. Cousins MJ. Acute pain and the injury response: immediate and prolonged effects. Reg Anesth 1989; 14:162-179.
11. Raja SN, Meyer RA, Campbell JN. Peripheral mechanisms of somatic pain. Anesthesiology 1988; 68:571-590.
12. McCormack K. Nonsteroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994; 59:9-43.
13. Kroin JS, Buvanendran A, McCarthy RJ, et al. Cyclooyxgenase-2 (COX-2) inhibitor potentiates morphine antinociception at the spinal level in a postoperative pain model. Reg Anesth Pain Med 2002; 27:451-455.
14. Dai YQ, Jin DZ, Zhu XZ, et al. Triptolide inhibits COX-2 expression via NF-kappa B pathway in astrocytes. Neuroscience 2006; 55:154-160.
15. Samad TA, Sapirstein A, Woolf CJ. Prostanoids and pain: unraveling mechanisms and revealing therapeutic targets. Trends Mol Med 2002; 8:390-396.
16. Samad TA, Moore KA, Sapirstein A, et al. Interleukin-1beta mediated induction of COX-2 in the CNS contributes inflammatory pain hypersensitivity. Nature 2001; 410:471-475.
17. Laflamme N, Lacroix S, Rivest S. An essential role of interleukin-1beta in mediating NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia. J Neurosci 1999; 19:10923-10930.
18. Reuben SS, Buvanendran A, Kroin JS, et al. Postoperative modulation of central nervous system prostaglandins E2 by cyclooxygenase inhibitors after vascular surgery. Anesthesiology 2006; 104:411-416. This clinical investigation demonstrates that cerebrospinal fluid prostaglandin E2 is elevated following surgical incision despite adequate spinal anesthesia. Further, NSAIDs crossing the blood-brain barrier are more effective in reducing this prostanoid.
19. Buvanendran A, Kroin JS, Berger RA, et al. Up-regulation of prostaglandin E2 and interleukins in the central nervous system and peripheral tissue during and after surgery in humans. Anesthesiology 2006; 104:403-410.
20. Dembo G, Park SB, Kharasch ED. Central nervous system concentration of cyclooxygenase-2 inhibitors in humans. Anesthesiology 2005; 102:409-415.
21. White PF. The role of nonopioid analgesic techniques in the management of pain after ambulatory surgery. Anesth Analg 2002; 94:577-585.
22. Souter AJ, Fredman B, White PF. Controversies in the perioperative use of nonsteroidal anti-inflammatory drugs. Anesth Analg 1994; 79:1178-1190.
23. Reuben SS, Connelly NR, Lurie SD, et al. Dose-response of ketorolac as an adjunct to patient-controlled analgesia morphine in patients after spinal fusion surgery. Anesth Analg 1998; 87:98-102.
24. Dahl JB, Kehlet H. Nonsteroidal anti-inflammatory drugs: rationale for use in severe postoperative pain. Br J Anaesth 1991; 66:703-712.
25. Moote C. Efficacy of nonsteroidal anti-inflammatory drugs in the management of postoperative pain. Drugs 1992; 44:14-30.
26. Reuben SS, Buvanendran A, Kroin JS, Raghunathan K. Evaluation of the analgesic efficacy of administering celecoxib, pregabalin and their combination for spinal fusion surgery. Anesth Analg 2006; 103:1271-1277. This study demonstrates that celecoxib alone reduces pain and opioid use, without reducing side effects. When combined with pregabalin, however, these two analgesics provided more effective analgesia while reducing opioid-related side effects.
27. Gilron I, Tod D, Goldstein DH, et al. The relationship between movement-evoked versus spontaneous pain and peak expiratory flow after abdominal hysterectomy. Anesth Analg 2002; 95:1702-1707.
28. Koch-Weser J. Nonsteroidal antiinflammatory drugs. N Engl J Med 1980; 302:1179-1185.
29. Joris J. Efficacy of nonsteroidal anti-inflammatory drugs in postoperative pain. Acta Anaesth Belg 1996; 47:115-123.
30. Bandolier Oxford League Table. Available at: http://www.jr2.ox.ac.uk/ bandolier/booth/painpag/Acuterev/Analgesics/Leagtab/html. [Accessed July 2007]
31. Edwards JE, Oldman AD, Smith LA, et al. Oral aspirin in postoperative pain: a quantitative systematic review. Pain 1999; 81:289-297.
32. Gajraj NM. Cyclooxygenase-2 inhibitors. Anesth Analg 2003; 96:1720-1738.
33. Sinatra R. Role of COX-2 inhibitors in the evolution of acute pain management. J Pain Symptom Manage 2002; 24:S18-S27.
34. Gilron I, Milne B, Hong M. Cyclooxygenase-2 inhibitors in postoperative pain management. Anesthesiology 2003; 99:1198-1208.
35. Stephens J, Laskins B, Pashos C, Wong J. The burden of acute postoperative pain and the potential role of the COX-2 specific inhibitors. Rheumatology 2003; 42:40-52.
36. Zemmel MH. The role of COX-2 inhibitors in the perioperative setting: efficacy and safety - a systematic review. AANA J 2006; 74:49-60. This is an excellent systematic review of the safety and efficacy of coxib use in the perioperative setting.
37. Straube S, Derry S, McQuay HJ, Moore RA. Effect of preoperative COX-II selective NSAIDs (coxibs) on postoperative outcomes: a systematic review of randomized studies. Acta Anaesthesiol Scand 2005; 49:601-613.
38. Romsing J, Moniche S. A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different COX-2 inhibitors for postoperative pain. Acta Anaesthesiol Scand 2004; 48:525-546.
39. Reuben SS. The safety and efficacy of perioperative COX-2 administration. Acta Anaesthesiol Scand 2005; 49:424.
40. Leese PT, Hubbard RC, Karim A, et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000; 40:124-132.
41. Reuben SS, Fingeroth R, Krushell R, Maciolek H. Evaluation of the safety and efficacy of the perioperative administration of rofecoxib for total knee arthroplasty. J Arthroplasty 2002; 17:26-31.
42. Connelly CS, Panush RS. Should nonsteroidal anti-inflammatory drugs be stopped before elective surgery? Arch Intern Med 1991; 151:1963-1966.
43. Robinson CM, Christie J, Malcom-Smith N. Nonsteroidal antiinflammatory drugs, perioperative blood loss, and transfusion requirements in elective hip arthroplasty. J Arthroplasty 1993; 8:607-610.
44. Brander VA, Stulberg SD, Adams AD, et al. Predicting total knee replacement pain. A prospective, observational study. Clin Orthop 2003; 416:27-36.
45. Reuben SS, Buvanendran A. Preventing the development of chronic pain after orthopaedic surgery with preventive multimodal analgesic techniques. J Bone Joint Surg Am 2007; 89:1343-1358. This excellent review article outlines the benefits of utilizing NSAIDs as a component of a preventive multimodal analgesic technique.
46. Buvanendran A, Kroin JS, Tuman KJ, et al. Effects of perioperative administration of a selective cyclooxygenase 2 inhibitor of pain management and recovery of function after knee replacement. JAMA 2003; 290:2411-2418.
47. Barden J, Edwards JE, McQuay HJ, Moore RA. Single-dose rofecoxib for acute postoperative pain in adults: a quantitative systematic review. BMC Anesthesiol 2002; 2:4.
48. Barden J, Edwards JE, Moore RA, McQuay HJ. Single dose oral rofecoxib for postoperative pain. Cochrane Database Syst Rev 2005; 1:CD004604.
49. Barden J, Edwards JE, McQuay HJ, Moore RA. Single dose oral celecoxib for postoperative pain. Cochrane Database Syst Rev 2003; 2:CD004233.
50. Barden J, Edwards JE, McQuay HJ, Moore RA. Oral valdecoxib and injected parecoxib for acute postoperative pain: a quantitative systematic review. BMC Anesthesiol 2003; 3:1-8.
51. Celebrex [Package insert]. New York: Pfizer; 2004.
52. Recart A, Issioui T, White PF, et al. The efficacy of celecoxib premedication on postoperative pain and recovery times after ambulatory surgery: a dose-ranging study. Anesth Analg 2003; 96:1631-1635.
53. Reuben SS, Ekman E. The effect of cyclooxygenase-2 inhibition on analgesia and spinal fusion. J Bone Joint Surg Am 2005; 87:536-542.
54. Reuben SS, Connelly NR. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Anesth Analg 2000; 91:1221-1225.
55. Tramer M, Williams J, Carroll D. Comparing analgesic efficacy of nonsteroidal anti-inflammatory drugs given by different routes in acute and chronic pain: a qualitative systematic review. Acta Anesth Scand 1998; 42:71-79.
56. Browning RC, Johnson K. Reducing the dose of oral NSAIDs by use of feldene gel: an open study in elderly patients with osteoarthritis. Adv Ther 1994; 11:198-206.
57. Vanderstraeten G, Schuermans P. Study on the effect of etofenamate 10% cream in comparison with an oral NSAID in strains and sprains due to sports injuries. Acta Belg Med Phys 1990; 13:139-141.
58. Berner G, Engels B, Vogtle-Junkert U. Percutaneous ibuprofen therapy with Trauma-Dolgit gel: bioequivalence studies. Drugs Exp Clin Res 1989; 15:559-564.
59. Evans JMM, McMahon A, McGilchrist M, et al. Topical nonsteroidal antiinflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. BMJ 1995; 311:22-26.
60. Moore RA, Carroll D, Wiffen PJ, et al. Quantitative systematic review of topically-applied nonsteroidal anti-inflammatory drugs. BMJ 1998; 316: 333-338.
61. Romsing J, Moniche S, Ostergaard D, Dahl JB. Local infiltration of NSAIDs for postoperative analgesia: evidence for a peripheral analgesic action. Acta Anaesthesiol Scand 2000; 44:672-683.
62. Rice AS, Lloyd J, Bullingham RE, O'Sullivan G. Ketorolac penetration into the cerebrospinal fluid of humans. J Clin Anesth 1993; 5:459-462.
63. Quadir M, Zia H, Needham TE. Development and evaluation of nasal formulations of ketorolac. Drug Deliv 2000; 7:223-229.
64. Vyas TK, Shahiwala A, Marathe S, et al. Intranasal drug delivery for brain targeting. Curr Drug Deliv 2005; 2:165-175.
65. Toradol IV/IM [Package insert]. Nutley, NJ: Roche Laboratories; 1994.
66. Eisenach JC, Curry R, Hood DD, Yaksh TL. Phase I safety assessment of intrathecal ketorolac. Pain 2002; 99:599-604.
67. Woolf CJ, Chong MS. Preemptive analgesia: treating postoperative pain by preventing the establishment of central sensitization. Anesth Analg 1993; 77:362-379.
68. Moniche S, Kehlet H, Dahl JB. A qualitative and quantitative systematic review of preemptive analgesia for postoperative pain relief: the role of timing of analgesia. Anesthesiology 2002; 96:725-741.
69. Ong CK, Lirk P, Seymour RA, Jenkins BJ. The efficacy of preemptive analgesia for acute postoperative pain management: a meta-analysis. Anesth Analg 2005; 100:757-773.
70. Katz J. Preemptive analgesia: importance of timing. Can J Anaesth 2001; 48:105-114.
71. Kissin I. Preemptive analgesia. Why its effect is not always obvious. Anesthesiology 1996; 84:1015-1019.
72. Reuben SS, Bhopatkar S, Maciolek H, et al. The preemptive analgesic effect of rofecoxib after ambulatory arthroscopic knee surgery. Anesth Analg 2002; 94:55-59.
73. Heigi TR, Bombeli T, Seifert B, et al. Effect of rofecoxib on platelet aggregation and blood loss in gynaecological and breast surgery compared with diclofenac. Br J Anaesth 2004; 92:523-531.
74. Celik JB, Tuncer S, Reisli R, et al. A comparative study of the effect of rofecoxib (a COX 2 inhibitor) with naproxen sodium on analgesic requirements after abdominal hysterectomy. Arch Gynecol Obstet 2003; 268:297-300.
75. Gopikrishna V, Parameswaran A. Effectiveness of prophylactic use of rofecoxib in comparison with ibuprofen on postendodontic pain. J Endod 2003; 29:62-64.
76. Kissin I. Preemptive analgesia: terminology and clinical relevance. Anesth Analg 1994; 79:809-810.
77. Reuben SS, Ekman EF, Raghunathan K, et al. The effect of cyclooxygenase-2 inhibition on acute and chronic donor-site pain after spinal-fusion surgery. Reg Anesth Pain Med 2006; 31:6-13. This prospective randomized trial demonstrates a reduction in both acute and chronic pain following the perioperative administration of celecoxib.
78. Remy C, Marret E, Bonnet F. Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials. Br J Anaesth 2005; 94:505-513.
79. Marrett E, Kurdi O, Zufferey P, Bonnet F. Effects of nonsteroidal antiinflammatory drugs on patient-controlled analgesia morphine side effects. Meta-analysis of randomized controlled trials. Anesthesiology 2005; 102:1249-1260.
80. Elia N, Lysakowski C, Tramer MR. Does multimodal analgesia with acetaminophen, nonsteroidal anti-inflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Anesthesiology 2005; 103:1296-1304.
81. Romsing J, Moniche S, Dahl JB. Reduction of opioid-related adverse events using opioid-sparing analgesia with COX-2 inhibitors lacks documentation: A systematic review. Acta Anaesthesiol Scand 2005; 49:133-142.
82. Kranke P, Morin AM, Roewer N, Eberhart LH. Patients' global evaluation of analgesia and safety of injected parecoxib for postoperative pain: a quantitative systematic review. Anesth Analg 2004; 99:797-806.
83. Apfelbaum JL, Gan TJ, Zhao S, et al. Reliability and validity of the preoperative opioid-related symptom distress scale. Anesth Analg 2004; 99:699-709.
84. Zhao SZ, Chung F, Hanna DB, et al. Dose-response relationship between opioid use and adverse events after ambulatory surgery. J Pain Symptom Manage 2004; 28:35-46.
85. Gan TJ, Joshi GP, Zhao SZ, et al. Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after laparoscopic cholecystectomy surgery reduces opioid requirements and opioid-related adverse effects. Acta Anaesthesiol Scand 2004; 48:1194-1207.
86. Reuben SS, Ekman EF, Charron D. Evaluating the analgesic efficacy of administering celecoxib as a component of multimodal analgesia for outpatient anterior cruciate ligament reconstruction surgery. Anesth Analg 2007; 105:222-227.
87. Reuben SS, Ekman EF. The effect of initiating a preventive multimodal analgesic regimen upon long-term patient outcomes for outpatient anterior cruciate ligament reconstruction surgery. Anesth Analg 2007; 105:228-232. This clinical trial demonstrates the long-term benefits of utilizing celecoxib as part of a preventive multimodal analgesic regimen for orthopedic surgery.
88. Gottschalk A, Smith DS. New concepts in acute pain therapy: preemptive analgesia. Am Fam Physician 2001; 63:1979-1984.
89. Cousins MJ, Power I, Smith G. 1996 Labat lecture: Pain: a persistent problem. Reg Anesth Pain Med 2000; 25:6-21.
90. Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain 1993; 52:259-285.
91. Vasquez E, Bär KJ, Ebersberger A, et al. Spinal prostaglandins are involved in the development but not the maintenance of inflammation-induced spinal hyperexcitability. J Neuroscience 2001; 21:9001-9008.
92. Hefferan MP, Carter P, Haley M, Loomis CW. Spinal nerve injury activates prostaglandin synthesis in the spinal cord that contributes to early maintenance of tactile allodynia. Pain 2003; 101:139-147.
93. Takeda K, Sawamura S, Tamai H, et al. Role for cyclooxygenase-2 in the development and maintenance of neuropathic pain and spinal glial activation. Anesthesiology 2005; 103:837-844.
94. Hefferan MP, O'Rielly DD, Loomis CW. Inhibition of spinal prostaglandin synthesis early after L5/L6 nerve ligation prevents the development of prostaglandin-dependent and prostaglandin-independent allodynia in the rat. Anesthesiology 2003; 99:1180-1188.
95. Gajraj NM. The effect of cyclooxygenase-2 inhibitors on bone healing. Reg Anesth Pain Med 2003; 28:456-465.
96. Dumont AS, Verma S, Dumont RJ, Hurlbert J. Nonsteroidal anti-inflammatory drugs on bone metabolism in spinal fusion surgery. A pharmacological quandary. J Pharmacol Toxicol Methods 2000; 43:31-39.
97. Maxy RJ, Glassman SD. The effect of nonsteroidal anti-inflammatory drugs on osteogenesis and spinal fusion. Reg Anesth Pain Med 2001; 26:156-158.
98. Wedel DJ, Berry D. He said, she said, NSAIDs. Reg Anesth Pain Med 2003; 28:372-375.
99. Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG. The role of prostaglandins in the regulation of bone metabolism. Clin Orthop 1995; 313:36-46.
100. Gerstenfeld LC, Thiede M, Seibert K, et al. Differential inhibition of fracture healing by nonselective and cyclooxygenase-2 selective nonsteroidal antiinflammatory drugs. J Orthop Res 2003; 21:670-675.
101. Gerstenfeld LC, Einhorn TA. COX inhibitors and their effects on bone healing. Expert Opin Drug Saf 2004; 3:131-136.
102. Reuben SS, Ablett D, Kaye R. High dose nonsteroidal anti-inflammatory drugs compromise spinal fusion. Can J Anaesth 2005; 52:506-512.
103. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343:1520-1528.
104. Egan KM, Wang M, Fries S, et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005; 111:334-342.
105. McAdam BF, Byrne D, Morrow JD, Oates JA. Contribution of cyclo-oxygenase-2 to elevated biosynthesis of thromboxane A2 and prostacyclin in cigarette smokers. Circulation 2005; 112:1024-1029.
106. Silverstein FE, Faich G, Goldstein JI, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. JAMA 2000; 284:1247-1255.
107. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutics Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomized controlled trial. Lancet 2004; 364:665-674.
108. Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients:SUCCESS-1 Study. Am J Med 2006;119:255-266.
109. Cannon CP, Curtis SP, Bolognese JA, Laine L, MEDAL Steering Committee. Clinical trial design and patient demographics of the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) study program: cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. Am Heart J 2006; 152:237-245.
110. Farkouh ME, Greenberg JD, Jeger RV, et al. Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. Ann Rheum Dis 2007; 66:764-770.
111. Graham DJ, Campen D, Hui R, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and nonselective nonsteroidal anti-inflammatory drugs: nested case-control study. Lancet 2005; 365:475-481.
112. Young D. FDA labors over NSAID decisions: panel suggests COX-2 inhibitors stay available. Am J Health Syst Pharm 2005; 62:6988-7072.